検索
Biodexa Pharmaceuticals PLC
BDRXウォッチリストに追加
2.940USD
-0.060-2.00%
終値 07/02, 13:00（ET）15分遅れの株価
1.33M時価総額
16.87直近12ヶ月PER
詳細情報 Biodexa Pharmaceuticals PLC 企業名
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Biodexa Pharmaceuticals PLCの企業情報
企業コードBDRX
会社名Biodexa Pharmaceuticals PLC
上場日Dec 08, 2014
最高経営責任者「CEO」Stamp (Stephen A)
従業員数- -
証券種類Depository Receipt
決算期末Dec 08
本社所在地1 Caspian Point
都市ABINGDON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United Kingdom
郵便番号CF10 4DQ
電話番号4401235888300
ウェブサイトhttps://www.biodexapharma.com/
企業コードBDRX
上場日Dec 08, 2014
最高経営責任者「CEO」Stamp (Stephen A)
Biodexa Pharmaceuticals PLCの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
よくある質問
Biodexa Pharmaceuticals PLCの上位5名の株主は誰ですか？
Biodexa Pharmaceuticals PLCの上位5名の株主は以下のとおりです。Dr. Simon Turton
Biodexa Pharmaceuticals PLC（BDRX）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Biodexa Pharmaceuticals PLCの株式を保有している機関は26社あり、保有株式の総市場価値は約66.51Kで、全体の7.79%を占めています。2025Q4と比較して、機関の持ち株は60313.00増加しています。